Is Panbela Therapeutics Inc. (NASDAQ: PBLA) Still On The Rise?

After Hours

It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. The stock was recently discussed on Yahoo Finance as it revealed that Panbela Announces Closing of Approximately $9.0 Million Public Offering.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

Stocks Info

Panbela Therapeutics Inc. is listed on the NASDAQ in the Healthcare sector while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $1.24 and fluctuated between $1.2600 as its day high and $1.1000 as its day low. The current market capitalization of Panbela Therapeutics Inc. is $6.03M. A total of 0.56 million shares were traded on the day, compared to an average of 0.78 shares.

Insider trades are also considered as indicators of how a stock will perform in the future, in addition to stock predictions. During the recent three months, PBLA has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 0 BUYs and 2 SELLs from insiders. Insiders purchased 0 shares during that period but sold 73,149.

In the most recent transaction, GOLDMAN SACHS GROUP INC sold 72,874 shares of PBLA for 0.71 per share on Nov 08. After the transaction, the 10% Owner now owns 397,954 company shares.

Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. According to analysts who have offered 12-month price targets for PBLA in the last 3 months, the mean price target is $410.00 with high estimates of $500.00 and low estimates of $320.00. In terms of 52-week highs and lows, PBLA has a high of $930.00 and a low of $1.06.

As of this writing, PBLA has an earnings estimate of -$24.34 per share for the current quarter. EPS was calculated based on a consensus of 2 estimates, with a high estimate of -$20.28 per share and a lower estimate of -$28.4. The company reported an EPS of -$159.08 in the last quarter, which was -69.10% lower than expectations of -$94.1.

Balance Sheet Annually/Quarterly

As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information. PBLA’s latest balance sheet shows that the firm has $11.87M in Cash & Short Term Investments as of fiscal 2021. Its Book Value Per Share was -$16.57, while its Total Shareholder’s Equity was $10.21M.

Analysts Opinion

After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for PBLA is Buy with a score of 5.00.

Most Popular

Related Posts